Keywords: zentiva, says, 2b, sanofi, bid, undervalues, firm
Zentiva says $2B Sanofi bid undervalues firm
Article | 15 September 2008
Czech generic drugmaker Zentiva has updated shareholders on its rejection of French drug major Sanofi-Aventis' 1.6 billion-euro ($2.33 billion; Marketletter July 21) bid ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
